Novavax, Inc. (NVAX)
- Previous Close
14.40 - Open
14.37 - Bid 12.97 x 2800
- Ask 13.02 x 600
- Day's Range
12.95 - 14.38 - 52 Week Range
3.53 - 15.00 - Volume
13,762,449 - Avg. Volume
12,781,523 - Market Cap (intraday)
1.916B - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-3.05 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
www.novavax.comRecent News: NVAX
Performance Overview: NVAX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVAX
Valuation Measures
Market Cap
1.92B
Enterprise Value
1.67B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.26
Price/Book (mrq)
--
Enterprise Value/Revenue
2.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-40.01%
Return on Assets (ttm)
-16.32%
Return on Equity (ttm)
--
Revenue (ttm)
996.61M
Net Income Avi to Common (ttm)
-398.71M
Diluted EPS (ttm)
-3.05
Balance Sheet and Cash Flow
Total Cash (mrq)
480.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.2B
Research Analysis: NVAX
Company Insights: NVAX
NVAX does not have Company Insights